Skip to content


You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Proceedings

Open Access

The role of genetic polymorphisms at the chromosomes 5p15, 6p12, 6p21 and 15q25 in non-small-cell lung cancer prognosis: a Portuguese prospective study

  • Ramon A de Mello1, 2Email author,
  • Mónica Ferreira3, 4,
  • Filipa S Pires5,
  • Sandra Costa3, 4,
  • Michael Luis2,
  • João Cunha6,
  • Pedro Oliveira7,
  • Venceslau Hespanhol1, 5 and
  • Rui M Reis3, 4, 8
BMC Proceedings20137(Suppl 2):P57

Published: 4 April 2013


Genome Wide Association Study (GWAS) variants on chromosome 15q25 and 5p15 and genetic polymorphisms on the vascular endothelial growth factor (VEGF) gene showed that they may contribute to lung carcinogenesis. Therefore, this study was performed in order to assess the role of GWAS, and VEGF variants in non-small-cell lung cancer (NSCLC) prognosis.

Materials and methods

Prospective study from February 2010 to April 2011. Median follow up was 12 months. NSCLC patient’s genotyping was performed using the Sequenom® MassARRAY platform. Kaplan-Meier curve was used to assess overall survival (OS) and progression-free-survival (PFS). Statistical significance was considered for p < 0.05.


144 NSCLC patients were consecutively genotyped in order to assess 19 single nucleotide polymorphisms (SNPs). Males were 78.5%. Median age was 61.5 (32 – 89) years-old. Non-squamous cell histology was 77.1% and 91.4% were stages IIIB and IV. The following SNPs showed influence in OS: rs2010963 (VEGF + 405 G/C), p = 0.042, rs3025010 (VEGF intron 5 C/T), p = 0.047, rs401681 C/T on 5p15, p = 0.046, rs31489 C/A on 5p15, p = 0.029; and these SNPs showed influence in PFS: rs9295740 G/A on 6p21, p = 0.074, rs401681 C/T on 5p15, p = 0.021.


This was the first large study in Portugal involving NSCLC patients and assessment of 19 SNPs on chromosome 5p15.33, 6p12, 6p21, 6p21.3, and 15q25. Our study suggests that variants on chromosome 5p15 and 6p21 are prognostic biomarkers in advanced NSCLC. In the future, genome-identified patients may improve NSCLC screening strategies and therapeutic management.

Financial support

University of Minho, FAPESP and CAPES.

Authors’ Affiliations

Department of Medicine, Faculty of Medicine University of Porto
Department of Medical Oncology, Portuguese Oncology Institute
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho
3B's - PT Government Associate Laboratory
Department of Pneumology, Centro Hospitalar de São João
Department of Pneumology, Hospital de Braga
Department of Populations Studies, ICBAS, Universidade do Porto
Molecular Oncology Research Center, Barretos Cancer Hospital


© de Mello et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.